DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksClose Window
References
Finn RS, Ryoo B-Y, Merle P. , et al.
Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC).
J Clin Oncol 2019;
37: 4004-4004
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.